<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="section" /><meta name="keywords" content="Infections: vaccines; Vaccines: active immunity; Immunisation; Immunity: active; Vaccines: active immunity: cautions; Vaccines: active immunity: contra-indication; Excipients: vaccines and; Vaccines: active immunity: pregnancy; Vaccines: active immunity: breast-feeding; Vaccines: active immunity: side-effects; Vaccines: post-immunisation pyrexia; Pyrexia: post immunisation; Paracetamol: post-immunisation pyrexia; Ibuprofen: post-immunisation pyrexia; AIDS: vaccines and; Vaccination: HIV-positive subjects; Asplenia: vaccines and" /><meta name="IX" content="Infections: vaccines; Vaccines: active immunity; Immunisation; Immunity: active; Vaccines: active immunity: cautions; Vaccines: active immunity: contra-indication; Excipients: vaccines and; Vaccines: active immunity: pregnancy; Vaccines: active immunity: breast-feeding; Vaccines: active immunity: side-effects; Vaccines: post-immunisation pyrexia; Pyrexia: post immunisation; Paracetamol: post-immunisation pyrexia; Ibuprofen: post-immunisation pyrexia; AIDS: vaccines and; Vaccination: HIV-positive subjects; Asplenia: vaccines and" /><title>14.1 Active immunity: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="6451.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="6451.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=6451.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2081.htm">14 Immunological products and vaccines</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="2081.htm" title="Previous: 14 Immunological products and vaccines">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="38311.htm" title="Next: Immunisation schedule">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_6451">14.1 Active immunity</h1><?highlighter on?><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i757.htm" title="Go to appendix 1">Vaccines</a>).</div><div><p>Active immunity can be acquired by natural disease
or by vaccination. <b>Vaccines</b> stimulate production
of antibodies and other components of the immune mechanism; they consist
of either:</p><ol class=""><li><p class="cQ">a <i>live attenuated </i>form of a virus (e.g.
measles, mumps and rubella vaccine) or bacteria (e.g. BCG vaccine),
or</p></li><li><p class="cQ"><i>inactivated</i> preparations of the virus
(e.g. influenza vaccine) or bacteria, or</p></li><li><p class="cQ"><i>detoxified exotoxins</i> produced by a micro-organism
(e.g. tetanus vaccine), or</p></li><li><p class="cQ"><i>extracts of</i> a micro-organism, which may
be derived from the organism (e.g. pneumococcal vaccine) or produced
by recombinant DNA technology (e.g. hepatitis B vaccine).</p></li></ol><p><b>Live attenuated vaccines</b> usually produce a
durable immunity, but not always as long-lasting as that resulting
from natural infection.</p><p><b>Inactivated vaccines</b> may require a primary
series of injections of vaccine to produce an adequate antibody response,
and in most cases booster (reinforcing) injections are required; the
duration of immunity varies from months to many years. Some inactivated
vaccines are adsorbed onto an adjuvant (such as <span>aluminium
hydroxide</span>) to enhance the antibody response.</p><div id="_202661"><div class="cN"><p>Advice in this chapter reflects that in the handbook <i>Immunisation against Infectious Disease</i> (2006), which in
turn reflects the guidance of the Joint Committee on Vaccination and
Immunisation (JCVI).</p><p>Chapters from the handbook are available at <a href="http://www.dh.gov.uk/immunisation" title="external link">www.dh.gov.uk/immunisation</a></p><p>The advice in this chapter also incorporates changes announced
by the Chief Medical Officer and Health Department Updates.</p></div></div><div id="_201082"><div class="cAZ"><h2>Cautions</h2> <p class="cAX"><span id="_202012">Most individuals
can safely receive the majority of vaccines. Vaccination
may be postponed if the individual is suffering from an acute illness;
however, it is not necessary to postpone immunisation in patients
with minor illnesses without fever or systemic upset</span>. See also Predisposition to Neurological Problems,
below. For individuals with bleeding disorders, see Route of administration,
below. <span id="_202216">If alcohol or disinfectant is used for cleansing the
skin it should be allowed to evaporate before vaccination to prevent
possible inactivation of live vaccines</span>.</p><p><span id="_202217">When 2 or more vaccines
are required (and are not available as a combined preparation), they
should be given simultaneously at different sites, preferably in a
different limb; if more than one injection is to be given in the same
limb, they should be administered at least 2.5 cm apart (but see also <a title="BNF:monograph-family: BCG vaccines" href="6457.htm#_6457">BCG Vaccines</a>). When 2 live vaccines cannot
be given at the same time, they should be separated by an interval
of at least 4 weeks</span>.<span id="_211905"></span><span id="_211906"></span><span id="_211903"></span> For <b>interactions</b> see Appendix 1 (vaccines).</p><p><i>See also</i> Cautions under individual vaccines </p></div></div><div id="_6451.4"><div class="cAZ" id="_202010"><h2>Contra-indications</h2> <p class="cAX"><span id="_202013">Vaccines are contra-indicated
in those who have a confirmed anaphylactic reaction to
a preceding dose of a vaccine containing the same antigens or vaccine
component (such as antibacterials in viral vaccines).
The presence of the following excipients in vaccines and immunological products has
been noted under the relevant entries:</span></p><div class="cN"><table class="table" cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;"><colgroup><col /><col /></colgroup><tbody><tr><td style="text-align: left;">Gelatin<br />Gentamicin<br />Kanamycin<br />Neomycin</td><td style="text-align: left;">Penicillins<br />Polymyxin B<br />Streptomycin<br />Thiomersal</td></tr></tbody></table></div> <p class="cAX"><i>Hypersensitivity to egg</i> with evidence of previous
anaphylactic reaction, contra-indicates tick-borne encephalitis vaccine
and yellow fever vaccine. Individuals with a history of egg allergy
can be immunised with either an egg free influenza vaccine, if available,
or an influenza vaccine with an ovalbumin content less than 120 nanograms/mL
(facilities should be available to treat anaphylaxis). If an influenza
vaccine containing ovalbumin is being considered in those with a history
of anaphylaxis to egg or egg allergy with uncontrolled asthma, these
individuals should be referred to a specialist in hospital. See also <a title="BNF:monograph: MEASLES, MUMPS AND RUBELLA VACCINE, LIVE" href="201183.htm#_201183">Cautions under MMR vaccine</a>.</p><p>See also Vaccines and HIV infection, below.</p><p>Live vaccines may be contra-indicated temporarily in individuals
who are:</p><ul class="cBF"><li><p class="cQ">immunosuppressed (see Impaired immune response, below);</p></li><li><p class="cQ">pregnant (see Pregnancy and breast-feeding, below).</p></li></ul><p><i>See also</i> Contra-indications under individual
vaccines.</p><div><h3 class="cAE">Impaired immune response</h3> <p class="cAE"><span id="_202014">Immune response to vaccines may be reduced in immunosuppressed patients and there is also a risk of generalised infection with live vaccines. Severely immunosuppressed patients should not be given live vaccines (including those with severe primary immunodeficiency). </span><span id="_202015">Specialist
advice should be sought for those being treated with high doses of
corticosteroids</span> (dose equivalents of prednisolone: <b>adults</b>, at least 40 mg daily for more than 1 week; <b>children</b>, 2 mg/kg daily for at least 1 week or 1 mg/kg daily
for 1 month), or other immunosuppressive drugs<sup class="footnote"><a title="Go to footnote" href="6451.htm#footnote113110">(1)</a></sup>, and those being treated for malignant
conditions with chemotherapy or generalised radiotherapy<sup class="footnote"><a title="Go to footnote" href="6451.htm#footnote113110">(1)</a></sup><sup class="footnote"><a title="Go to footnote" href="6451.htm#footnote119679">(2)</a></sup>. For special reference to <i>HIV
infection</i>, see below.</p></div><p>The Royal College of Paediatrics and Child
Health has produced a statement, <i>Immunisation of the Immunocompromised
Child (2002)</i> (available at <a href="http://www.rcpch.ac.uk" title="external link">www.rcpch.ac.uk</a>).</p></div></div><div id="_208981"><div class="cAZ"><h2>Pregnancy</h2> <p class="cAX">Live vaccines should not be administered routinely
to <i>pregnant women</i> because of the theoretical risk
of fetal infection but where there is a significant risk of exposure
to disease (e.g. to yellow fever), the need for vaccination usually
outweighs any possible risk to the fetus. Termination of pregnancy
following inadvertent immunisation is not recommended. There is no
evidence of risk from vaccinating pregnant women with inactivated
viral or bacterial vaccines or toxoids. For use of specific vaccines
during pregnancy, see under individual vaccines.</p></div></div><div id="_208980"><div class="cAZ"><h2>Breast-feeding</h2> <p class="cAX">Although there is a theoretical
risk of live vaccine being present in breast milk, vaccination is
not contra-indicated for women who are breast-feeding when there is
significant risk of exposure to disease. There is no
evidence of risk from vaccinating women who are breast-feeding, with
inactivated viral or bacterial vaccines or toxoids. For use of specific
vaccines during breast-feeding, see under individual vaccines.</p></div></div><div id="_201084"><div class="cAZ" id="_120022"><h2>Side-effects</h2> <p class="cAX">Injection of a vaccine may be followed by
local reactions such as pain, inflammation, redness, and lymphangitis.
An induration or sterile abscess may develop at the injection site.
Gastro-intestinal disturbances, fever, headache, irritability, loss
of appetite, fatigue, myalgia, and malaise are among the most commonly
reported side-effects. Other side-effects include influenza-like symptoms,
dizziness, paraesthesia, asthenia, drowsiness, arthralgia, rash, and
lymphadenopathy. Hypersensitivity reactions, such as bronchospasm,
angioedema, urticaria, and anaphylaxis, are very rare but can be fatal
(see <a title="monograph-family: Anaphylaxis" href="201198.htm#_201198">section 3.4.3</a> for management of allergic emergencies).</p><p><b>Oral</b> vaccines such as cholera, live poliomyelitis,
rotavirus, and live typhoid can also cause gastro-intestinal disturbances
such as nausea, vomiting, abdominal pain and cramps, and diarrhoea.</p><p><i>See also</i> Predisposition to neurological problems,
below.</p><p>Some vaccines (e.g. poliomyelitis) produce very few reactions,
while others (e.g. measles, mumps and rubella) may cause a very mild
form of the disease. Occasionally more serious adverse reactions can
occur—these should always be reported to the CHM (see <a title="prelim-section: Adverse reactions to drugs" href="29432.htm#_29432">Adverse Reactions to Drugs</a>).</p><p>See also <a title="BNF:target-block: Prematurity" href="38311.htm#_201730">Preterm Birth</a>.</p><div class="cN"><h3 class="cBP">Post-immunisation pyrexia in infants</h3><p>The
parent should be advised that if pyrexia develops after childhood
immunisation, and the infant seems distressed, a dose of paracetamol
can be given and,
if necessary, a second dose can be given 6 hours later; ibuprofen
may be used if paracetamol is unsuitable. The parent should be warned
to seek medical advice if the pyrexia persists.</p><p>For post-immunisation pyrexia in an infant aged 2–3 months,
the dose of paracetamol is 60 mg; the dose of ibuprofen is 50 mg (on
a doctor’s advice). An oral syringe can be obtained from any pharmacy
to give the small volume required.</p></div><div id="_201080"><div class="cN"><h3 class="cBP">Predisposition to neurological problems</h3><p> When there is a personal or family history of <i>febrile</i> convulsions, there is an increased risk of these occurring during
fever from any cause including immunisation, but this is not a contra-indication
to immunisation. In children who have had a seizure associated with
fever without neurological deterioration, immunisation is <i>recommended</i>; advice on the <i>management of fever</i> (see Post-immunisation pyrexia in infants, above) should be given
before immunisation. When a child has had a convulsion not associated
with fever, and the neurological condition is not deteriorating, immunisation
is <i>recommended</i>.</p><p>Children with stable neurological disorders (e.g. spina bifida,
congenital brain abnormality, and perinatal hypoxic-ischaemic encephalopathy)
should be immunised according to the recommended schedule.</p><p>When there is a <i>still evolving neurological problem</i>, including poorly controlled epilepsy, immunisation should be <i>deferred</i> and the child referred to a specialist. Immunisation
is recommended if a cause for the neurological disorder is identified.
If a cause is not identified, immunisation should be deferred until
the condition is stable.</p></div></div><p>Further information on adverse effects associated
with specific vaccines can be found under individual vaccines.</p></div></div><div id="_200189"><div class="cAZ"><h2>Vaccines and HIV infection</h2> <p class="cAX"><span id="_201859"></span><span id="_202016"></span><span id="_201862"></span><span id="_201863"></span>HIV-positive individuals with or
without symptoms can receive the following live vaccines:</p><ul class="cBD"><li><p class="cQ">MMR (but avoid if immunity significantly impaired), varicella-zoster
(but avoid if immunity significantly impaired—consult product literature);<sup class="footnote"><a title="Go to footnote" href="6451.htm#footnote119679">(2)</a></sup></p></li></ul><p>and the following inactivated vaccines:</p><ul class="cBD"><li><p class="cQ">anthrax, cholera (oral), diphtheria, haemophilus influenzae
type b, hepatitis A, hepatitis B, human papilloma virus, influenza,
meningococcal, pertussis, pneumococcal, poliomyelitis, rabies, tetanus,
tick-borne encephalitis, typhoid (injection).</p></li></ul><p>HIV-positive individuals should <b>not </b>receive:</p><ul class="cBD"><li><p class="cQ">BCG, typhoid (oral), yellow fever<sup class="footnote"><a title="Go to footnote" href="6451.htm#footnote113115">(3)</a></sup></p></li></ul><div class="cAR"><h3>Note</h3> <p class="cAX">The above advice differs from that for other
immunocompromised patients; <i>Immunisation Guidelines for HIV-infected
Adults</i> issued by <i>British HIV Association</i> (BHIVA) are available at <a href="http://www.bhiva.org" title="external link">www.bhiva.org</a> and, <i>Immunisation  of HIV-infected Children</i> issued by <i>Children’s HIV Association</i> (CHIVA) are
available at <a href="http://www.chiva.org.uk" title="external link">www.chiva.org.uk</a></p></div></div></div><div id="_6451.5"><div class="cAZ"><h2>Vaccines and asplenia</h2> <p class="cAX">The following vaccines are recommended for
asplenic patients or those with splenic dysfunction:</p><ul class="cBD"><li><p class="cQ">haemophilus influenzae type b; influenza; meningococcal
A, C, W135, and Y conjugate; pneumococcal.</p></li></ul><p>For antibiotic prophylaxis in asplenia see <a title="sub-topic: Prevention of pneumococcal infection in asplenia or in patients with sickle cell disease" href="102052.htm#_102052">Table 2. Summary of Antibacterial
Prophylaxis</a>.</p></div></div><div id="_201685"><div class="cAZ"><h2>Route of administration</h2> <p class="cAX"><span id="_202197">Vaccines should not be given intravenously</span>. Most vaccines are given by the intramuscular route; some vaccines
are given by others routes—the intradermal route for BCG vaccine,
deep subcutaneous route for Japanese encephalitis, and varicella vaccine,
and the oral route for cholera, live poliomyelitis, rotavirus, and
live typhoid vaccines. The intramuscular route should not be used
in patients with <b>bleeding disorders</b> such as haemophilia
or thrombocytopenia. Vaccines usually given by the intramuscular route
should be given by deep subcutaneous injection instead.</p></div><div class="cAR"><h3>Note</h3> <p class="cAX">The Department of Health has advised <i>against the use of jet guns</i> for vaccination owing to the
risk of transmitting blood-borne infections, such as HIV.</p></div></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_38311"><a href="38311.htm" title="Immunisation schedule">Immunisation schedule</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="2081.htm">Previous: 14 Immunological products and vaccines</a> | <a class="top" href="6451.htm#">Top</a> | <a accesskey="]" href="38311.htm">Next: Immunisation schedule</a> ►</div><div class="cF"><div class="footnote" id="footnote113110"><sup>(1)</sup>Live vaccines should be postponed until at least 3 months after
stopping high-dose systemic <span>corticosteroids</span> and
at least 6 months after stopping other immunosuppressive drugs or
generalised radiotherapy (at least 12 months after discontinuing immunosuppressants
following bone-marrow transplantation).</div><div class="footnote" id="footnote119679"><sup>(2)</sup>Use of normal immunoglobulin should be considered after exposure
to measles (see <a title="BNF:target-block: normal immunoglobulin measles" href="202710.htm#_6539.2">Normal Immunoglobulin</a>) and varicella–zoster immunoglobulin considered
after exposure to chickenpox or herpes zoster (see <a title="BNF:monograph-family: Varicella–zoster" href="202721.htm#_202721">Varicella-Zoster</a>).</div><div class="footnote" id="footnote113115"><sup>(3)</sup>If yellow fever risk is unavoidable, specialist advice should
be sought.</div></div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>